An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)
Overview
- Phase
- Phase 3
- Intervention
- cisplatin
- Conditions
- Not specified
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Enrollment
- 412
- Locations
- 531
- Primary Endpoint
- Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
- Status
- Active, not recruiting
- Last Updated
- 12 days ago
Overview
Brief Summary
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced).
In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Investigators
Clinical Trial Information
Scientific
Seagen Inc.
Eligibility Criteria
Inclusion Criteria
- •Histopathological confirmation of locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including UC originating from the renal pelvis, ureters, bladder, or urethra.
- •Measurable disease by investigator assessment per RECIST v1.
- •Participant must not have received prior systemic therapy for LA/mUC. Exception will be made for neoadjuvant or adjuvant therapy, if disease recurrence/progression occurred more than 12 months after the last dose of therapy.
- •Eligible to receive cisplatin- or carboplatin-containing chemotherapy.
- •Able to provide archived formalin-fixed paraffin-embedded tumor tissue blocks from a muscle-invasive or metastatic UC lesion or biopsy of metastatic UC prior to treatment initiation. If archival tissue is not available a newly obtained baseline biopsy of an accessible tumor lesion is required within 28 days of cycle 1 day
- •HER2 expression of 1+ or greater on immunohistochemistry (IHC).
- •Eastern Cooperative Oncology Group (ECOG) performance score of 0, 1, or 2 within 7 days prior to randomization.
Exclusion Criteria
- •Known hypersensitivity to disitamab vedotin, cisplatin, carboplatin, gemcitabine, or pembrolizumab or any of their components.
- •History of severe/life threatening immune-related adverse event (irAE) with PD-(L)1 inhibitors are excluded.
- •Central nervous system (CNS) and/or leptomeningeal metastasis. Participants with treated CNS metastases are permitted if all of the following are met.
- •CNS metastases have been clinically stable for at least 4 weeks and baseline scans show no evidence of new or worsening CNS metastasis.
- •Participant is on a stable dose of ≤ 10 mg/day of prednisone or equivalent for at least 2 weeks.
- •History of or active autoimmune disease that has required systemic treatment in the past 2 years.
- •Prior treatment with an agent directed to another stimulatory or co-inhibitory T cell receptor (including but not limited to CD137 agonists, CAR-T cell therapy, CTLA-4 inhibitors, or OX-40 agonists).
- •Prior solid organ or bone marrow transplantation.
- •Pleural effusion or ascites with symptoms or requiring symptomatic treatment.
- •Estimated life expectancy \<12 week
Arms & Interventions
Standard of care arm
gemcitabine + cisplatin OR carboplatin
Intervention: cisplatin
Standard of care arm
gemcitabine + cisplatin OR carboplatin
Intervention: carboplatin
Disitamab vedotin arm
disitamab vedotin + pembrolizumab
Intervention: pembrolizumab
Disitamab vedotin arm
disitamab vedotin + pembrolizumab
Intervention: disitamab vedotin
Standard of care arm
gemcitabine + cisplatin OR carboplatin
Intervention: gemcitabine
Outcomes
Primary Outcomes
Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by blinded independent central review (BICR)
Time Frame: Approximately 3 years
The time from randomization to first documentation of disease progression per RECIST v1.1 by BICR, or to death due to any cause.
Overall survival (OS)
Time Frame: Approximately 5 years
The time from date of randomization to date of death due to any cause.
Secondary Outcomes
- Number of electrocardiogram (ECG) abnormalities(Through 30 days after the last study treatment; approximately 2 years)
- Change from baseline of left ventricular ejection fraction (LVEF)(Through 2 years after last study treatment; approximately 4 years)
- Objective response rate (ORR) per RECIST v1.1 by BICR(Approximately 3 years)
- ORR per RECIST v1.1 by investigator assessment(Approximately 3 years)
- Duration of Response (DOR) per RECIST v1.1 by BICR(Approximately 3 years)
- Treatment discontinuation rate due to AEs(Approximately 2 years)
- DOR per RECIST v1.1 by investigator assessment(Approximately 3 years)
- Control Rate (DCR) per RECIST v1.1 by BICR(Approximately 3 years)
- DCR per RECIST v1.1 by investigator assessment(Approximately 3 years)
- PFS per RECIST v1.1 by investigator assessment(Approximately 3 years)
- Number of participants with adverse events (AEs)(Through 30 days after the last study treatment; approximately 2 years)
- Number of participants with laboratory abnormalities(Through 30 days after the last study treatment; approximately 2 years)
- Change from baseline to Week 16 in European Organization for Research and Treatment of Cancer core Quality of Life questionnaire (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score(Approximately 2 years)
- Time to Deterioration in EORTC QLQ-C30 GHS/QoL Score(Approximately 2 years)
- Time to pain progression(Approximately 2 years)